| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCK |
| Uniprot No | P07108 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-104aa |
| 氨基酸序列 | WGDLWLLPPASANPGTGTEAEFEKAAEEVRHLKTKPSDEEMLFIYGHYKQATVGDINTERPGMLDFTGKAKWDAWNELKGTSKEDAMKAYINKVEELKKKYGI |
| 预测分子量 | 15.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇与CCK重组蛋白相关的模拟参考文献示例(非真实文献，供参考)：
1. **《Expression and Purification of Recombinant Human CCK in E. coli》**
- 作者：Li, X. et al.
- 摘要：研究通过大肠杆菌表达系统高效生产重组人源CCK蛋白，优化了诱导条件及纯化步骤，获得高纯度活性蛋白，适用于体外受体结合实验。
2. **《Functional Characterization of Recombinant CCK-8 in Neuronal Signaling》**
- 作者：Smith, J.R. & García, M.
- 摘要：利用哺乳动物细胞表达系统制备CCK-8重组蛋白，验证其对中枢神经元CCK-B受体的激活作用，证实其在调控焦虑行为中的潜在应用价值。
3. **《Development of a CCK-2 Receptor-Specific Agonist Using Recombinant Protein Engineering》**
- 作者：Wang, Y. et al.
- 摘要：通过基因工程改造CCK重组蛋白，增强其对CCK-2受体的选择性，为胃肠癌靶向治疗药物的开发提供新候选分子。
注：以上文献为示例，实际引用请通过PubMed或学术数据库检索真实研究。
**Background of CCK Recombinant Protein**
Cholecystokinin (CCK), a peptide hormone and neuropeptide, is widely distributed in the gastrointestinal tract and central nervous system. Initially discovered for its role in stimulating gallbladder contraction and pancreatic enzyme secretion, CCK also functions as a neurotransmitter involved in satiety signaling, anxiety modulation, and pain perception. Structurally, CCK exists in multiple bioactive forms (e.g., CCK-8. CCK-33) derived from a precursor protein through post-translational processing. These variants bind to CCK receptors (CCKR), primarily CCK-A and CCK-B subtypes, which are G protein-coupled receptors (GPCRs) mediating diverse physiological responses.
Recombinant CCK protein is engineered using biotechnological methods, such as *E. coli* or mammalian expression systems, to produce high-purity, standardized CCK peptides for research and therapeutic applications. The recombinant approach ensures precise control over post-translational modifications (e.g., sulfation of tyrosine residues critical for receptor affinity) and scalability. This technology overcomes limitations of natural extraction, such as low yield and heterogeneity.
CCK recombinant proteins are vital tools in studying CCK signaling pathways, receptor-ligand interactions, and their roles in diseases like obesity, gastrointestinal disorders, and neurological conditions. They also hold potential in drug development, particularly for targeting CCKR in cancer, metabolic syndromes, and psychiatric disorders. Challenges remain in optimizing bioactivity and stability, but advances in protein engineering continue to enhance their utility. Overall, CCK recombinant proteins bridge basic research and clinical innovation, offering insights into complex physiological networks and therapeutic opportunities.
×
